- Company
- New oral psoriasis drug 'Sotyktu' available in hospitals
- by Eo, Yun-Ho May 14, 2024 05:48am
- An oral psoriasis drug 'Sotyktu' is becoming available for prescription at general hospitals. According to industry sources, BMS Korea’s Sotyktu (deucravacitinib) has passed the drug committee (DC) of hospitals, including Seoul Asan Hospital, Severance Hospital, Konyang University Hospital, Soonchunghyang University Bucheon Hospital, Se
- Company
- Ryvrevant to lead market with Exkivity’s market withdrawal
- by Son, Hyung-Min May 14, 2024 05:48am
- Exkivity, a treatment for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation, is being withdrawn from the market. The highly anticipated oral treatment failed to demonstrate efficacy in a confirmatory clinical trial, leading to its market withdrawal. With no competition, Rybrevant is expected to remain the market leader
- Policy
- New dementia drug Leqembi’s approval imminent in Korea
- by Lee, Hye-Kyung May 14, 2024 05:48am
- The marketing authorization for Leqembi (lecanemab), the first drug to slow the progression of Alzheimer's disease, is imminent in Korea. According to industry sources on the 14th, the Ministry of Food and Drug Safety (MFDS) completed the safety and efficacy review of ‘Leqembi (lecanemab),’ a new drug for Alzheimer's disease that was co-
- Company
- AbbVie’s Aquipta becomes the first oral CGRP migraine drug
- by Son, Hyung-Min May 13, 2024 05:52am
- For the first time, an oral CGRP drug has been introduced for the treatment of migraine. AbbVie’s Aquipta has shown positive results as a preventive treatment for chronic migraine as well as episodic migraine in patients who have failed up to 4 prior oral preventive treatments. Experts believe that the benefits of being an oral formulation
- Company
- BeiGene reapplies for Tevimbra’s reimb in esophageal cancer
- by Eo, Yun-Ho May 13, 2024 05:52am
- BeiGene is again attempting reimbursement for its immunotherapy, ‘Tevimbra (tislelizumab)’ in Korea. According to industry sources, BeiGene Korea recently submitted an application for the reimbursement of its Tevimbra (tiselizumab) and is waiting for the Health Insurance Review and Assessment Service's Cancer Disease Review Committee’s
- Company
- MM drug Tecvayli can be prescribed in tertiary hospitals
- by Eo, Yun-Ho May 13, 2024 05:52am
- The new multiple myeloma drug ‘Tecvayli’ can now be prescribed in tertiary hospitals in Korea. According to industry sources, Janssen Korea’s multiple myeloma drug Tecvayli (teclistamab) has passed the drug committee (DC) review of top tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Se
- Company
- Pharma companies showcase their R&D achievements
- by Son, Hyung-Min May 13, 2024 05:52am
- Pharmaceutical companies have disclosed the development outcomes of the obesity treatments, which have now become the trending R&D. As obesity treatments of the GLP-1 class, such as those of Novo Nordisk and Lilly, become blockbuster new drugs globally, the development of latecomers is on the rise. Major companies plan to develop the next-
- Policy
- SGLT-2 monotherapy 'Suglat' set to withdraw from KOR
- by Lee, Tak-Sun May 13, 2024 05:51am
- The SGLT-2 inhibitor 'Suglat tab 50 mg (Ipragliflozin L-Proline),' which is used as monotherapy, will no longer be available in the market in South Korea. Three SGLT-2 monotherapies that were imported will be withdrawn from the Korean market, as Steglatro and Forxiga are set to be withdrawn. According to the Ministry of Food and Drug
- Company
- Hanmi’s 2 new accounts of the pipeline enter clinical trial
- by Son, Hyung-Min May 13, 2024 05:51am
- Hanmi Pharm is accelerating the development of new obesity drugs. Following efpeglenatide, which has entered the Phase 3 trial in South Korea, Hanmi Pharm’s other new drug candidate has entered the full-scale clinical trial. Furthermore, Hanmi Pharm plans to establish various pipelines, including an oral agent, digital therapy related to obesit
- Company
- HSF therapy 'Altuviiio' receives Orphan Drug designation
- by Eo, Yun-Ho May 10, 2024 04:33pm
- 'Altuviiio,' a once-weekly administered hemophilia A new drug, has been designated as Korea’s Orphan Drug. The Ministry of Food and Drug Safety (MFDS) announced this in a recent posting. Sanofi-Aventis Korea’s Altuviiio (efanesoctocog alfa) is a first-in-class high sustained factor (HSF) therapy for hemophilia A. With once-weekly
